DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Netherlands Cancer Institute
Amsterda, HolandaPublicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (17)
2023
-
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
Cancer Medicine, Vol. 12, Núm. 11, pp. 12071-12083
-
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)
Nature Medicine
2022
-
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
European Urology, Vol. 82, Núm. 2, pp. 212-222
-
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
Nature communications, Vol. 13, Núm. 1, pp. 1878
2021
-
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 4, pp. 525-537
-
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Future Oncology, Vol. 17, Núm. 2, pp. 137-149
-
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma
European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091
-
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice
The Journal of urology, Vol. 206, Núm. 2, pp. 240-251
-
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
European urology oncology, Vol. 4, Núm. 3, pp. 456-463
2020
-
Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer[Formula presented]
European Urology, Vol. 77, Núm. 2, pp. 269-276
-
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588
-
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)
Nature Medicine
2019
-
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Nature Medicine, Vol. 25, Núm. 11, pp. 1706-1714
2018
2017
-
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic- and tumor-related biomarkers for response and toxicity
Urologic Oncology: Seminars and Original Investigations, Vol. 35, Núm. 8, pp. 529.e9-529.e16
2016
2015
-
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
British Journal of Cancer, Vol. 113, Núm. 1, pp. 12-19